TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20375422

Group type: EXPERIMENTAL
Intervention: 0.2 g of fish oil emulsion/kg infusion for 14 days
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: 0.05 g of fish oil/kg oral capsules after infusion
Number of subjects: 23

Group type: COMPARATOR
Intervention: 0.9% saline infusion (placebo) for 14 days
Number of subjects: 23

Group type: COMPARATOR
Intervention: Paraffin wax oral capsules (placebo) after infusion
Number of subjects: 23
Study: 18415808

Group type: EXPERIMENTAL
Intervention: Inhaled budesonide (800 microg daily, 6 months)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Oral prednisolone (30 mg daily, 3 weeks)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 15942291

Group type: EXPERIMENTAL
Intervention: Active Cycle of Breathing Techniques (ACBT)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Acapella
Number of subjects: 20
Study: 12501127

Group type: EXPERIMENTAL
Intervention: +Calanolide A
Number of subjects: 47
Study: 10411559

Group type: EXPERIMENTAL
Intervention: Omeprazole (i.v. administration in therapeutic doses)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Omeprazole (in vitro)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Omeprazole (in vivo)
Number of subjects: 0
Study: 7480549

Group type: EXPERIMENTAL
Intervention: Alprazolam 0.5 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Alprazolam 1.5 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Adinazolam 15 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Adinazolam 45 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Alprazolam (high dose) vs Adinazolam (high dose)
Number of subjects: 12
Study: 2344898

Group type: EXPERIMENTAL
Intervention: Amiodarone
Number of subjects: 68

Group type: COMPARATOR
Intervention: Quinidine
Number of subjects: 68
Study: 7006345

Group type: EXPERIMENTAL
Intervention: Cinoxacin at a dosage of 500 mg b.i.d.
Number of subjects: 100

Group type: COMPARATOR
Intervention: Nalidixic acid at a dosage of 1 g q.i.d.
Number of subjects: 100
Study: 31647325

Group type: EXPERIMENTAL
Intervention: Annual on-site monitoring
Number of subjects: 4371

Group type: COMPARATOR
Intervention: No on-site monitoring
Number of subjects: 4371
Study: 30644124

Group type: EXPERIMENTAL
Intervention: RAPIT recovery program delivered by nurses
Number of subjects: 386
Study: 28548228

Group type: EXPERIMENTAL
Intervention: PBM (near-infrared 839/595 nm)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo-PBM (595 nm)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: PBM (30 minutes MAL-incubation)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo-PBM (30 minutes MAL-incubation)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: PBM (90 minutes MAL-incubation)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo-PBM (90 minutes MAL-incubation)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: PBM (180 minutes MAL-incubation)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo-PBM (180 minutes MAL-incubation)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: PBM and Placebo-PBM
Number of subjects: 20
Study: 26217089

Group type: EXPERIMENTAL
Intervention: Risk prediction scoring model (based on age ≥ 40 years, total bilirubin ≥ 171 μmol/L, prothrombin activity 40%‐60%, hepatitis B virus DNA > 107 copies/mL)
Number of subjects: 1457
Study: 23001540

Group type: EXPERIMENTAL
Intervention: Resinous extract from Commiphora swynnertonii at 400 mg/kg bodyweight
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Resinous extract from Commiphora swynnertonii at 800 mg/kg bodyweight
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Anticoccidial drug
Number of subjects: 80

Group type: COMPARATOR
Intervention: Normal saline (placebo)
Number of subjects: 80
Study: 21124045

Group type: EXPERIMENTAL
Intervention: Transtympanic steroid injection (4 courses of methylprednisolone after conventional treatment)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Conventional steroid treatment
Number of subjects: 76
Study: 19747585

Group type: EXPERIMENTAL
Intervention: Whole body vibration training (2x5‐min/day, Frequency: 20Hz; amplitude: 2‐4mm)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control intervention (no vibration training)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control intervention
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Whole body vibration training
Number of subjects: 8
Study: 16847610

Group type: EXPERIMENTAL
Intervention: Transmastoidal galvanic vestibular stimulation (GVS) at two different intensities
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normal vision
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Blurring vision
Number of subjects: 0
Study: 15672278

Group type: EXPERIMENTAL
Intervention: TRUS lesion guided biopsy
Number of subjects: 217

Group type: COMPARATOR
Intervention: Systematic sextant biopsy
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: Both biopsy strategies
Number of subjects: 217
Study: 11372906

Group type: EXPERIMENTAL
Intervention: Pharmaceutical care services
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional pharmacy care
Number of subjects: 0
Study: 9230805

Group type: EXPERIMENTAL
Intervention: Nissen fundoplication (complete wrap)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Toupet fundoplication (partial wrap)
Number of subjects: 39
Study: 8431045

Group type: EXPERIMENTAL
Intervention: Continuous extrapleural intercostal nerve block
Number of subjects: 20

Group type: COMPARATOR
Intervention: Lumbar epidural morphine
Number of subjects: 20
Study: 2890442

Group type: EXPERIMENTAL
Intervention: pancuronium 0.12 mg.kg‐1
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: vecuronium 0.12 mg.kg‐1
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: atracurium 0.4 mg.kg‐1
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: pancuronium‐metocurine mixture (0.4 mg + 1.6 mg/ml): 1 ml/10 kg
Number of subjects: 60
Study: 31286293

Group type: EXPERIMENTAL
Intervention: Reference pegfilgrastim (PG)
Number of subjects: 250

Group type: COMPARATOR
Intervention: Potentially biosimilar test product
Number of subjects: 250
Study: 26856250

Group type: EXPERIMENTAL
Intervention: Risperidone after 2 weeks
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: Risperidone after 9 months (CATIE confirmatory analysis)
Number of subjects: 183
Study: 26337017

Group type: EXPERIMENTAL
Intervention: Coffee polyphenol extract (CPE) beverage
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo beverage
Number of subjects: 19
Study: 23324995

Group type: EXPERIMENTAL
Intervention: Pitavastatin (4 mg/day)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Pravastatin (20 mg/day)
Number of subjects: 101
Study: 21965490

Group type: EXPERIMENTAL
Intervention: Transmucosal herbal periodontal patch (THPP) for three days
Number of subjects: 53

Group type: COMPARATOR
Intervention: Placebo patches (PP) for three days
Number of subjects: 53
Study: 19828907

Group type: EXPERIMENTAL
Intervention: American ginseng supplementation (500 mg daily for 4 months)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo capsules
Number of subjects: 25
Study: 16735951

Group type: EXPERIMENTAL
Intervention: Estradiol therapy
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Estradiol and testosterone therapy
Number of subjects: 6

Group type: COMPARATOR
Intervention: No hormone therapy (untreated postmenopausal women)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Premenopausal women
Number of subjects: 6
Study: 15026296

Group type: EXPERIMENTAL
Intervention: Lyme disease vaccination
Number of subjects: 745
Study: 11303077

Group type: EXPERIMENTAL
Intervention: Gulf veterans
Number of subjects: 4795

Group type: COMPARATOR
Intervention: Non-Gulf veterans
Number of subjects: 4795
Study: 9595867

Group type: EXPERIMENTAL
Intervention: Rizatriptan 5 mg
Number of subjects: 1473

Group type: EXPERIMENTAL
Intervention: Rizatriptan 10 mg
Number of subjects: 1473

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1473
Study: 8085692

Group type: EXPERIMENTAL
Intervention: Combination chemotherapy plus radiation therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Interferon combined with psoralen plus ultraviolet A light therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adenosine analogs and retinoids
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Interferons
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Photopheresis therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Interleukin-2 fusion toxins and several antibody conjugates
Number of subjects: 0
Study: 3256648

Group type: EXPERIMENTAL
Intervention: Preparatory vulval cleansing before urine specimen collection
Number of subjects: 316

Group type: COMPARATOR
Intervention: No preparatory vulval cleansing before urine specimen collection
Number of subjects: 316
Study: 31955921

Group type: EXPERIMENTAL
Intervention: Routine care plus a web‐based self‐management intervention including individual e‐coaching and group meetings over a 3‐month intervention period, followed by e‐coaching over a 6‐month maintenance period.
Number of subjects: 99

Group type: COMPARATOR
Intervention: Routine care (control group).
Number of subjects: 99
Study: 30470147

Group type: EXPERIMENTAL
Intervention: Gaviscon Double Action liquid (20 ml)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 28128748

Group type: EXPERIMENTAL
Intervention: Fine-needle aspiration cytology (FNAC)
Number of subjects: 629

Group type: COMPARATOR
Intervention: Fine-needle non-aspiration cytology (FNNAC)
Number of subjects: 629
Study: 25871803

Group type: EXPERIMENTAL
Intervention: Morphine exposure
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Prematurity, opioid exposure and neonatal pain
Number of subjects: 19
Study: 23323867

Group type: EXPERIMENTAL
Intervention: Duodenal infusion of donor feces after an initial vancomycin regimen (500 mg orally four times per day for 4 days) followed by bowel lavage and subsequent infusion.
Number of subjects: 16

Group type: COMPARATOR
Intervention: Standard vancomycin regimen (500 mg orally four times per day for 14 days).
Number of subjects: 16

Group type: COMPARATOR
Intervention: Standard vancomycin regimen with bowel lavage.
Number of subjects: 16
Study: 21112925

Group type: EXPERIMENTAL
Intervention: Behavioral weight control (BWC) intervention for 16 weeks with 4 biweekly maintenance sessions
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Greater parent self-monitoring during the intervention
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Greater parent pressure to eat
Number of subjects: 86
Study: 20067164

Group type: EXPERIMENTAL
Intervention: Prospective randomized study on 559 diabetics from Timişoara
Number of subjects: 1184

Group type: EXPERIMENTAL
Intervention: Retrospective descriptive study on 625 diabetics from Petroşani
Number of subjects: 1184
Study: 17472115

Group type: EXPERIMENTAL
Intervention: Natalizumab
Number of subjects: 2

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 2
Study: 14709942

Group type: EXPERIMENTAL
Intervention: SRI treatment for 8 weeks
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control group (19 sex-matched and age-matched individuals)
Number of subjects: 19
Study: 11309437

Group type: EXPERIMENTAL
Intervention: Isotretinoin (30 mg/day) for 3 years
Number of subjects: 1166

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1166
Study: 9344429

Group type: EXPERIMENTAL
Intervention: Repeated taste group (same taste stimuli)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Changing taste group (different taste stimuli)
Number of subjects: 0
Study: 7875957

Group type: EXPERIMENTAL
Intervention: Protirelin tartrate 4 mg/die i.m.
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 2839020

Group type: EXPERIMENTAL
Intervention: Enalapril (n = 127)
Number of subjects: 253

Group type: COMPARATOR
Intervention: Placebo (n = 126)
Number of subjects: 253
Study: 31638960

Group type: COMPARATOR
Intervention: Intravenous TXA (1000 mg administered intravenously twice, just before surgery and 6 hours after)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Combined TXA (1000 mg of intra-articular TXA for each knee plus intravenous TXA as above)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Intravenous TXA
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Combined TXA
Number of subjects: 77
Study: 28577752

Group type: EXPERIMENTAL
Intervention: TR Band hemostasis with 10 cc of air for 1.5 hours
Number of subjects: 3616

Group type: COMPARATOR
Intervention: TR Band hemostasis with 13 cc of air for 4 hours
Number of subjects: 3616

Group type: EXPERIMENTAL
Intervention: TR Band hemostasis with 10 cc of air for 3 hours
Number of subjects: 3616

Group type: EXPERIMENTAL
Intervention: TR Band hemostasis with 10 cc of air for 2 hours
Number of subjects: 3616

Group type: EXPERIMENTAL
Intervention: TR Band hemostasis with less than 13 cc of air
Number of subjects: 3616

Group type: EXPERIMENTAL
Intervention: TR Band hemostasis with more than 1.5 hours
Number of subjects: 3616
Study: 26268494

Group type: EXPERIMENTAL
Intervention: Micro‐movement sensitive mattress sleep monitoring system (MSMSMS)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Polysomnography (PSG)
Number of subjects: 61
Study: 22752758

Group type: EXPERIMENTAL
Intervention: At-home portable monitoring (PMhome)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Simultaneous PM and polysomnography (PSG+PM)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Polysomnography (PSG)
Number of subjects: 43
Study: 21231926

Group type: EXPERIMENTAL
Intervention: Interpersonal psychotherapy plus pharmacotherapy (IPT)
Number of subjects: 124

Group type: COMPARATOR
Intervention: Medication plus clinical management (CM)
Number of subjects: 124
Study: 18436027

Group type: EXPERIMENTAL
Intervention: 4% articaine with 1:100,000 epinephrine buccal infiltration
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: 4% articaine with 1:100,000 epinephrine infiltrations
Number of subjects: 31

Group type: COMPARATOR
Intervention: IANB using 2% lidocaine 1:80,000 epinephrine
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Buccal infiltration with articaine
Number of subjects: 31
Study: 22694733

Group type: EXPERIMENTAL
Intervention: Steroid-free (SF) immunosuppression
Number of subjects: 130

Group type: COMPARATOR
Intervention: Steroid-based (SB) immunosuppression
Number of subjects: 130
Study: 15754600

Group type: EXPERIMENTAL
Intervention: Fluidotherapy (heat at 46.7 degrees C - 48.9 degrees C and tactile stimulation)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Tactile stimulation alone
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 21
Study: 12610738

Group type: EXPERIMENTAL
Intervention: Topical budesonide (10(‐2) g/ml to 10(‐8) g/ml)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Inhaled budesonide (400 microg/day for 3 weeks)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Overall dose-cutaneous response effect
Number of subjects: 22

Group type: COMPARATOR
Intervention: Methacholine bronchial challenge testing
Number of subjects: 22

Group type: COMPARATOR
Intervention: Serum cortisol
Number of subjects: 22
Study: 10196655

Group type: EXPERIMENTAL
Intervention: Bismuth subgallate
Number of subjects: 204

Group type: COMPARATOR
Intervention: Plain swabs (Control)
Number of subjects: 204
Study: 7772456

Group type: EXPERIMENTAL
Intervention: AIDS-prevention workshop
Number of subjects: 62

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 62
Study: 2323135

Group type: EXPERIMENTAL
Intervention: Free patellar tendon autograft
Number of subjects: 19
Study: 527352

Group type: EXPERIMENTAL
Intervention: 20 mg penbutolol twice daily
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 30680400

Group type: EXPERIMENTAL
Intervention: Garlicin Capsules 1/time, 3 times/d combined with Kangfuxin liquid 10 mL gargle 3 times/d
Number of subjects: 204

Group type: COMPARATOR
Intervention: Kangfuxin liquid 10 mL gargle 3 times/d
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Garlicin Capsules combined with Kangfuxin liquid
Number of subjects: 204
Study: 26626861

Group type: EXPERIMENTAL
Intervention: Video glasses
Number of subjects: 83

Group type: COMPARATOR
Intervention: Control group (no video glasses)
Number of subjects: 83
Study: 24928338

Group type: EXPERIMENTAL
Intervention: Vilanterol (VI)
Number of subjects: 347

Group type: EXPERIMENTAL
Intervention: Salmeterol (SAL)
Number of subjects: 347

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 347
Study: 23121378

Group type: EXPERIMENTAL
Intervention: Aliskiren (300 mg daily)
Number of subjects: 8561

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8561
Study: 20445361

Group type: EXPERIMENTAL
Intervention: Hb(mass) measurement using the optimized carbon monoxide rebreathing method
Number of subjects: 11
Study: 18759524

Group type: EXPERIMENTAL
Intervention: Prophylactic oral metronidazole
Number of subjects: 311

Group type: COMPARATOR
Intervention: Control group (no metronidazole)
Number of subjects: 311
Study: 16784013

Group type: EXPERIMENTAL
Intervention: Lysine acetylsalicylate (LAS) and amphotericin B
Number of subjects: 115

Group type: COMPARATOR
Intervention: Lysine acetylsalicylate (LAS)
Number of subjects: 115
Study: 14665524

Group type: EXPERIMENTAL
Intervention: High-intensity exercise training (HI) [above the LT]
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Moderate-intensity exercise training (MOD) [below the LT]
Number of subjects: 18

Group type: COMPARATOR
Intervention: No exercise training (CON)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: High-intensity exercise training (HI)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Moderate-intensity exercise training (MOD)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: High-intensity exercise training (HI) and Moderate-intensity exercise training (MOD)
Number of subjects: 18
Study: 10973534

Group type: EXPERIMENTAL
Intervention: Mildly hypothermic CPB (32 degrees C)
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Normothermic CPB (37 degrees C)
Number of subjects: 144

Group type: COMPARATOR
Intervention: Comparison of both groups
Number of subjects: 144
Study: 8776693

Group type: EXPERIMENTAL
Intervention: Portacaval anastomosis (n = 20)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Nonsurgical therapy (n = 24)
Number of subjects: 44
Study: 1531004

Group type: COMPARATOR
Intervention: Group 1 (1980-1986) - 36 patients
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Group 2 (1987-Oct. 1990) - 37 patients
Number of subjects: 73
Study: 6333298

Group type: EXPERIMENTAL
Intervention: Intracoronary streptokinase followed by heparin
Number of subjects: 250

Group type: COMPARATOR
Intervention: Conventional therapy with heparin
Number of subjects: 250
Study: 31131359

Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery (LAP)
Number of subjects: 1057

Group type: COMPARATOR
Intervention: Open surgery (OP)
Number of subjects: 1057

Group type: EXPERIMENTAL
Intervention: Both LAP and OP
Number of subjects: 1057
Study: 29066131

Group type: EXPERIMENTAL
Intervention: TdaP(PTgen/FHA)
Number of subjects: 450

Group type: COMPARATOR
Intervention: Tdap (comparator)
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: aP(PTgen/FHA)
Number of subjects: 450
Study: 27246726

Group type: EXPERIMENTAL
Intervention: Cetuximab alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cetuximab with irinotecan
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cetuximab alone or with irinotecan
Number of subjects: 0
Study: 25154829

Group type: EXPERIMENTAL
Intervention: Maintenance Rituximab (MR)
Number of subjects: 289

Group type: COMPARATOR
Intervention: Re-treatment Rituximab (RR)
Number of subjects: 289

Group type: EXPERIMENTAL
Intervention: Both arms (RR and MR)
Number of subjects: 289
Study: 22525771

Group type: EXPERIMENTAL
Intervention: 75 g of glucose (Glu)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: 75 g of galactose (Gal)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 20488452

Group type: EXPERIMENTAL
Intervention: Comparing symbols group (instruction involving comparing the equal sign with greater than and less than symbols)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Equal sign group (instruction about the equal sign only)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no specific instruction mentioned)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Comparing symbols group
Number of subjects: 0
Study: 17851937

Group type: EXPERIMENTAL
Intervention: Microlaryngoscopy (MLS)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Septoplasty
Number of subjects: 43
Study: 16225492

Group type: EXPERIMENTAL
Intervention: Ferrous sulphate 100 mg twice a day
Number of subjects: 41

Group type: COMPARATOR
Intervention: Iron-polymaltose complex 200 mg once a day
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Comparison of treatments
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 41
Study: 12419719

Group type: EXPERIMENTAL
Intervention: Diazepam 0.1 mg*kg(‐1) orally 60 min preoperatively (Group I)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Diazepam 0.1 mg*kg(‐1) orally 90 min preoperatively (Group II)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo (Group III)
Number of subjects: 61
Study: 10365010

Group type: EXPERIMENTAL
Intervention: Levobupivacaine (0.25% w/v 50 ml)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Bupivacaine (0.25% w/v 50 ml)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Levobupivacaine
Number of subjects: 66

Group type: COMPARATOR
Intervention: Bupivacaine
Number of subjects: 66
Study: 7574352

Group type: EXPERIMENTAL
Intervention: Fibrin glue (5 ml containing 500 IU of thrombin) applied by spray in the area of axillary dissection
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (no fibrin glue)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Fibrin glue (group A)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (group B)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study: 2340347

Group type: EXPERIMENTAL
Intervention: Sublingual administration of vincamine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gastrointestinal absorption of vincamine dissolved in saliva
Number of subjects: 0
Study: 7029650

Group type: EXPERIMENTAL
Intervention: 200 micrograms/d of 15(R)‐15‐methyl prostaglandin E2 (MPGE2) for one month
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13